Copyright
©2012 Baishideng Publishing Group Co.
World J Hepatol. Nov 27, 2012; 4(11): 291-298
Published online Nov 27, 2012. doi: 10.4254/wjh.v4.i11.291
Published online Nov 27, 2012. doi: 10.4254/wjh.v4.i11.291
Table 1 Clinical characteristics, demographic data and laboratory data of 3857 cirrhotic patients
Parameter | All patients (n = 3857) | Survivors (n = 2375) | Non-survivors (n = 1482) | P value |
Age, yr | 60.73 ± 14.05 | 59.02 ± 14.02 | 63.48 ± 13.65 | < 0.001 |
Male, n (%) | 2665 (69.1) | 1651 (69.52) | 1014 (68.42) | NS (0.474) |
Hepatoma, n (%) | 1385 (35.9) | 653 (27.5) | 732 (49.4) | < 0.001 |
Cause of liver cirrhosis, n (%) | < 0.001 | |||
Hepatitis C | 930 (24.1) | 568 (23.9) | 362 (24.4) | - |
Hepatitis B | 1090 (28.3) | 631 (26.6) | 459 (31) | - |
Alcoholic | 813 (21.1) | 580 (24.4) | 233 (15.7) | - |
Hepatitis C + hepatitis B | 106 (2.7) | 70 (2.9) | 36 (2.4) | - |
Hepatitis C + alcohol | 60 (1.6) | 39 (1.6) | 21 (1.4) | - |
Hepatitis B + alcohol | 191 (5) | 127 (5.3) | 64 (4.3) | - |
Hepatitis C + hepatitis B + alcohol | 33 (0.9) | 19 (0.8) | 14 (0.9) | - |
Not hepatitis C, hepatitis B or alcohol | 634 (16.4) | 341 (14.4) | 293 (19.8) | - |
Ascites, n (%) | 1861 (48.2) | 825 (34.7) | 1036 (69.9) | < 0.001 |
Hepatic encephalopathy, n (%) | 1097 (28.4) | 434 (18.3) | 663 (44.7) | < 0.001 |
Child–Pugh points | 8.36 ± 2.57 | 7.11 ± 1.97 | 10.37 ± 2.1 | < 0.001 |
MELD score | 18.9 ± 10.26 | 13.15 ± 5.57 | 27.98 ± 9.36 | < 0.001 |
Albumin, 3.5-5 g/dL | 2.95 ± 0.73 | 3.24 ± 0.68 | 2.49 ± 0.55 | < 0.001 |
Total bilirubin, 0.3-1.2 mg/dL | 5.18 ± 8.16 | 2.24 ± 3.57 | 9.89 ± 10.81 | < 0.001 |
INR | 1.89 ± 1.75 | 1.43 ± 0.43 | 2.72 ± 2.55 | < 0.001 |
BUN, 8-12 mg/dL | 34.47 ± 35.55 | 17.63 ± 15.52 | 61.44 ± 41.49 | < 0.001 |
Creatinine, 0.4-1.2 mg/dL | 1.94 ± 1.91 | 1.27 ± 1.35 | 3.01 ± 2.17 | < 0.001 |
eGFR, mL/(min∙1.73 m-2) (MDRD-4) | 63.17 ± 46.12 | 79.14 ± 37.4 | 37.57 ± 47.24 | < 0.001 |
eGFR, mL/(min∙1.73 m-2) (MDRD-6) | 54.87 ± 38.25 | 70.85 ± 33.29 | 29.32 ± 31.16 | < 0.001 |
eGFR, mL/(min∙1.73 m-2) (CKD-EPI) | 65.39 ± 37.49 | 82.11 ± 30.28 | 38.59 ± 31.99 | < 0.001 |
Table 2 Univariate and multivariate logistic regression analyses of the various parameters in predicting in-hospital mortality
Parameter | Beta coefficient | Standard error | Odds ratios (95% CI) | P value |
Univariate logistic regression analysis | ||||
Age, yr | 0.02 | 0.00 | 1.02 (1.02-1.03) | < 0.001 |
Hepatoma | 0.95 | 0.07 | 2.57 (2.25-2.95) | < 0.001 |
Ascites | 1.47 | 0.07 | 4.36 (3.80-5.02) | < 0.001 |
Hepatic encephalopathy | 1.29 | 0.07 | 3.62 (3.13-4.19) | < 0.001 |
Cause of liver cirrhosis (reference group: NBNCNA) | ||||
Hepatitis C | -0.30 | 0.10 | 0.74 (0.61-0.91) | 0.004 |
Hepatitis B | -0.17 | 0.10 | 0.85 (0.70-1.03) | NS (0.098) |
Alcoholic | -0.76 | 0.11 | 0.47 (0.38-0.58) | < 0.001 |
Hepatitis C + hepatitis B | -0.51 | 0.22 | 0.60 (0.39-0.92) | 0.020 |
Hepatitis C + alcoholic | -0.53 | 0.17 | 0.59 (0.42-0.82) | 0.002 |
Hepatitis B + alcoholic | -0.15 | 0.36 | 0.86 (0.42-1.74) | NS (0.670) |
Hepatitis C + hepatitis B + alcoholic | -0.47 | 0.28 | 0.63 (0.36-1.09) | NS (0.098) |
Child–Pugh points | 0.67 | 0.02 | 1.95 (1.87-2.03) | < 0.001 |
MELD score | 0.22 | 0.01 | 1.25 (1.23-1.27) | < 0.001 |
BUN, mg/dL | 0.07 | 0.00 | 1.07 (1.06-1.07) | < 0.001 |
Creatinine, mg/dL | 0.72 | 0.03 | 2.05 (1.93-2.18) | < 0.001 |
eGFR, mL/(min∙1.73 m-2) (MDRD-4) | -0.04 | 0.00 | 0.97 (0.96-0.97) | < 0.001 |
eGFR, mL/(min∙1.73 m-2) (MDRD-6) | -0.05 | 0.00 | 0.95 (0.95-0.96) | < 0.001 |
eGFR, mL/(min∙1.73 m-2) (CKD-EPI) | -0.04 | 0.00 | 0.97 (0.96-0.96) | < 0.001 |
Albumin, g/dL | -1.97 | 0.07 | 0.14 (0.12-0.16) | < 0.001 |
Total bilirubin, mg/dL | 0.20 | 0.01 | 1.22 (1.20-1.25) | < 0.001 |
INR | 1.74 | 0.08 | 5.70 (4.87-6.67) | < 0.001 |
Multivariate logistic regression analysis | ||||
Age, yr | 0.03 | 0.01 | 1.03 (1.01-1.04) | < 0.001 |
Hepatoma | 0.95 | 0.13 | 2.60 (2.02-3.34) | < 0.001 |
Cause of liver cirrhosis (reference group: NBNCNA) | ||||
Hepatitis C | -0.19 | 0.18 | 0.83 (0.58-1.18) | NS (0.299) |
Hepatitis B | -0.28 | 0.19 | 0.76 (0.52-1.10) | NS (0.139) |
Alcoholic | -0.21 | 0.22 | 0.81 (0.52-1.25) | NS (0.342) |
Hepatitis C + hepatitis B | -1.03 | 0.40 | 0.36 (0.16-0.78) | 0.010 |
Hepatitis C + alcoholic | -0.79 | 0.35 | 0.46 (0.23-0.90) | 0.023 |
Hepatitis B + alcoholic | 0.32 | 0.57 | 1.38 (0.45-4.22) | NS (0.576) |
Hepatitis C + hepatitis B + alcoholic | 0.54 | 0.47 | 1.71 (0.68-4.29) | NS (0.354) |
MELD score | 0.14 | 0.03 | 1.14 (1.09-1.20) | < 0.001 |
BUN, mg/dL | 0.04 | 0.00 | 1.05 (1.04-1.05) | < 0.001 |
eGFR, mL/(min∙1.73 m-2) (MDRD-4) | 0.03 | 0.01 | 1.03 (1.02-1.04) | < 0.001 |
eGFR, mL/(min∙1.73 m-2) (MDRD-6) | -0.03 | 0.01 | 0.97 (0.95-0.99) | < 0.001 |
Albumin, g/dL | -1.24 | 0.13 | 0.29 (0.22-0.38) | < 0.001 |
INR | 0.24 | 0.10 | 1.27 (1.04-1.54) | 0.019 |
Table 3 Relationship between estimated glomerular filtration rate, total bilirubin, international normalized ratio and model for end-stage liver disease score as a predictor of in-hospital mortality
Model | Variable | Odds ratio (95% CI) | P value | χ2 | -2 Log Likelihood |
Model 1 | MELD | 1.25 (1.23-1.27) | < 0.001 | 2198.32 | 2773.90 |
Model 2 | Total bilirubin1 | 2.25 (2.05-2.48) | < 0.001 | 2161.45 | 2810.77 |
INR1 | 6.14 (4.56-8.27) | < 0.001 | |||
eGFR (MDRD-4)1 | 0.22 (0.20-0.25) | < 0.001 | |||
Model 3 | Total bilirubin1 | 2.17 (1.97-2.40) | < 0.001 | 2293.82 | 2664.79 |
INR1 | 5.95 (4.39- 8.06) | < 0.001 | |||
eGFR (MDRD-6)1 | 0.19 (0.17-0.22) | < 0.001 | |||
Model 4 | Total bilirubin1 | 2.26 (2.05-2.48) | < 0.001 | 2199.16 | 2773.07 |
INR1 | 6.28 (4.65-8.49) | < 0.001 | |||
eGFR (CKD-EPI)1 | 0.20 (0.18-0.23) | < 0.001 |
Table 4 Comparison of different models for end-stage liver disease equations for the prediction of in-hospital mortality
Equations | Odds ratio (95% CI) | P value | χ2 | -2 Log Likelihood |
MELD | 1.25 (1.23-1.27) | < 0.001 | 2198.32 | 2773.90 |
MELD-MDRD-4 | 1.27 (1.26-1.29) | < 0.001 | 2147.93 | 2824.30 |
MELD-MDRD-6 | 1.29 (1.27-1.31) | < 0.001 | 2254.88 | 2703.72 |
MELD-CKD-EPI | 1.28 (1.26-1.30) | < 0.001 | 2185.01 | 2787.21 |
Table 5 The difference between the model for end-stage liver disease and model for end-stage liver disease-modification of diet in renal disease-6 scores of differentially obtained estimated glomerular filtration rate for the prediction of in-hospital mortality
eGFR | Equations | Odds ratio (95% CI) | P value | χ2 | -2 Log Likelihood |
≥ 90 | MELD | 1.17 (1.13-1.21) | < 0.001 | 99.45 | 609.51 |
MELD-MDRD-6 | 1.20 (1.16-1.24) | < 0.001 | 114.55 | 588.67 | |
60-89 | MELD | 1.22 (1.18-1.26) | < 0.001 | 185.77 | 636.17 |
MELD-MDRD-6 | 1.27 (1.22 -1.32) | < 0.001 | 214.60 | 606.45 | |
30-59 | MELD | 1.21 (1.17-1.24) | < 0.001 | 283.21 | 755.92 |
MELD-MDRD-6 | 1.26 (1.22-1.30) | < 0.001 | 312.75 | 725.22 | |
15-29 | MELD | 1.25 (1.19-1.30) | < 0.001 | 163.72 | 369.37 |
MELD-MDRD-6 | 1.31 (1.24-1.39) | < 0.001 | 182.49 | 350.59 | |
< 15 | MELD | 1.36 (1.27-1.45) | < 0.001 | 190.62 | 311.89 |
MELD-MDRD-6 | 1.30 (1.23-1.39) | < 0.001 | 164.66 | 337.42 |
- Citation: Chen YW, Chang CW, Chang CW, Wang TE, Wu CJ, Chen HH. Is an estimated glomerular filtration rate better than creatinine to be incorporated into the end-stage liver disease score? World J Hepatol 2012; 4(11): 291-298
- URL: https://www.wjgnet.com/1948-5182/full/v4/i11/291.htm
- DOI: https://dx.doi.org/10.4254/wjh.v4.i11.291